New insights from the COMET randomized clinical trial, published on December 12, 2024, in JAMA Oncology, offer important evidence on the patient experience in managing low-risk ductal carcinoma in situ (DCIS).
This secondary analysis evaluated patient-reported outcomes (PROs) including quality of life, anxiety, depression, and treatment-related symptoms among 957 participants randomized to receive either guideline-concordant care (GCC: surgery ± radiation) or active monitoring (AM).
After 2 years of follow-up, results showed no significant differences between the two groups in most measures. Emotional well-being and symptom burden remained comparable, with only minor variations of limited clinical significance. These findings suggest that active monitoring may be a safe and acceptable option for select patients, offering reassurance without compromising quality of life.
Led by Dr. Ann Partridge and colleagues, this study reinforces the importance of individualized care and shared decision-making in breast oncology.
Full publication: https://lnkd.in/d4hFsbNZ
